If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Highlands Natural Resources, Immupharma, Versarien and Prospex Oil & Gas
Nick Tulloch, Finance Director of Highlands Natural Resources (HNR) discusses their recent trading update which includes their newly launched CBD operation.
Highlands is a diversified resources company whose principal assets are 8 producing wells east of Denver, Colorado and a vertically integrated premium CBD business.
Tim McCarthy, Chairman of ImmuPharma (IMM) talks about their recent fundraise and provides an update on their lead programme Lupuzor.
ImmuPharma (AIM: IMM) is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.
(Interview starts at 12 minutes 56 seconds)
Neill Ricketts, Chief Executive Officer of Versarien (VRS) discusses the appointment of Susan Bowen as a non-executive director.
Versarien is an advanced engineering materials group. Leveraging proprietary technology, the Group creates innovative engineering solutions for its clients in a diverse range of industries. Versarien has five subsidiaries operating under two divisions: Graphene and Plastics Thermal and Hardware Products.
(Interview starts at 23 minutes 48 seconds)
Ed Dawson, Managing Director of Prospex Oil & Gas (PXOG) explains the results of their Bainet-2 Well in Romania and also talks about other approaching milestones.
Prospex Oil and Gas Plc is an AIM quoted investment company focussed on high impact onshore and shallow offshore European opportunities with short timelines to production. The Company's strategy is to acquire undervalued projects with multiple, tangible value trigger points that can be realised within 12 months of acquisition and then applying low cost re-evaluation techniques to identify and de-risk prospects.
(Interview starts at 29 minutes 12 seconds)